Aktis Oncology (NASDAQ:AKTS) Now Covered by Bank of America

Analysts at Bank of America initiated coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research report issued to clients and investors on Tuesday. The brokerage set a “buy” rating and a $34.00 price target on the technology company’s stock. Bank of America‘s target price suggests a potential upside of 54.69% from the stock’s previous close.

A number of other equities analysts also recently weighed in on AKTS. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Leerink Partners began coverage on shares of Aktis Oncology in a research note on Tuesday. They issued an “outperform” rating and a $31.00 price objective on the stock. Finally, TD Cowen assumed coverage on shares of Aktis Oncology in a research report on Tuesday. They issued a “buy” rating for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.67.

Aktis Oncology Price Performance

Shares of AKTS stock opened at $21.98 on Tuesday. Aktis Oncology has a 1-year low of $18.52 and a 1-year high of $29.16.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc bought 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $39,999,996.00. Following the acquisition, the director directly owned 4,348,658 shares of the company’s stock, valued at $78,275,844. The trade was a 104.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the business’s stock in a transaction on Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the transaction, the insider owned 10,260,064 shares in the company, valued at approximately $184,681,152. The trade was a 12.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 6,117,776 shares of company stock valued at $110,119,968. 3.30% of the stock is owned by corporate insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.